Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than 50,000 people in Japan. The goal of […] The post Mosliciguat for PH-ILD granted orphan drug status in Japan appeared first on Pu...
